What Are the Main Apolipoprotein B Treatment Options?

Apolipoprotein B can be lowered through a layered strategy that starts with statins and lifestyle changes, then adds cholesterol-absorption blockers, injectable PCSK9-targeting drugs, and newer oral agents depending on how far your levels need to fall and how well you tolerate each step. Because each apoB-containing particle in your blood carries exactly one molecule of apoB, your apoB level is essentially a count of every potentially artery-clogging particle circulating in your bloodstream. That makes it a uniquely informative target, and the treatment toolkit for bringing it down has expanded considerably in the past decade.

Why ApoB Has Become a Treatment Target

Standard lipid panels report LDL cholesterol, which measures the amount of cholesterol riding inside LDL particles. The problem is that two people can have the same LDL-C number while carrying very different numbers of particles. A 2024 analysis published in JAMA Cardiology illustrated this vividly: at an LDL-C of 100 mg/dL, roughly half the population had apoB levels between 75 and 86 mg/dL, while the full range stretched from about 66 to 99 mg/dL.¹ That spread matters because having more particles means more opportunities for cholesterol to lodge in artery walls.

Data from the CARDIA Study followed young adults over 25 years and found that when apoB was high but LDL-C was low, the odds of developing coronary artery calcification were still significantly elevated. The reverse scenario, where LDL-C was high but apoB was low, did not carry the same excess risk after adjusting for other factors.² In other words, the particle count told the real story when it disagreed with the cholesterol measurement. Every atherogenic lipoprotein, whether it is LDL, VLDL, IDL, or lipoprotein(a), carries a single apoB molecule, making plasma apoB a direct tally of all those particles combined.³

Statins as the First-Line Approach

Statins remain the starting point for virtually everyone who needs apoB lowered. They work by blocking a key enzyme in cholesterol production inside the liver, which forces liver cells to pull more LDL particles out of the bloodstream to meet their cholesterol needs. A kinetic study in people with combined hyperlipidemia showed that both atorvastatin and simvastatin roughly doubled the rate at which the body cleared LDL apoB from the blood.⁴ That faster clearance is the main reason LDL-C and apoB both drop on a statin.

High-intensity statins, such as atorvastatin 40–80 mg or rosuvastatin 20–40 mg, typically lower apoB by somewhere around 40–50 percent. For many people that is enough to reach guideline-recommended levels. But the degree of apoB reduction does not always track perfectly with the LDL-C drop because particle size and composition vary from person to person, which is one reason clinicians increasingly check apoB directly.

Ezetimibe for Additional Lowering

If a statin alone does not get apoB low enough, ezetimibe is usually the next addition. Ezetimibe blocks cholesterol absorption in the small intestine, and a kinetic study in men with primary hypercholesterolemia found that it reduced the pool of LDL apoB by about 23 percent, driven mainly by faster clearance of apoB-100-containing lipoproteins from the blood.⁵ In practice, adding ezetimibe to a statin typically shaves off an additional 15–25 percent of LDL-C and a corresponding reduction in apoB. It is inexpensive, widely available as a generic, and well tolerated, making it an easy second step.

PCSK9 Inhibitors

For people who remain above target after maximizing statins and ezetimibe, PCSK9 inhibitors represent a powerful next tier. These are injectable antibodies, given every two to four weeks, that block a protein called PCSK9. Normally, PCSK9 tags LDL receptors on liver cells for destruction; when you block it, more receptors survive, and the liver pulls LDL particles out of the bloodstream much more aggressively.

Alirocumab, one of the two approved PCSK9 antibodies, reduced LDL apoB by about 56 percent in a study of healthy adults, an effect driven by an 80 percent jump in the rate at which the body cleared those particles.⁶ Evolocumab, the other approved antibody, produces similar LDL-C and apoB reductions and also lowers lipoprotein(a) in a dose-related fashion. A pooled analysis of over 1,300 patients across four trials showed mean Lp(a) reductions between roughly 25 and 30 percent.⁷ That Lp(a) effect matters because Lp(a) carries its own apoB molecule and contributes to total particle count.

Side effects in clinical trials have been mild for both drugs, mostly limited to injection-site reactions, upper respiratory symptoms, and occasional joint or back pain.⁸ The main barriers to wider use are cost and the need for regular injections, though both drugs have accumulated large cardiovascular outcomes trial data showing meaningful reductions in heart attacks and strokes.

Inclisiran and the Twice-a-Year Model

Inclisiran takes a different approach to silencing PCSK9. Instead of blocking the protein after it is made, inclisiran uses a small interfering RNA molecule to prevent liver cells from producing PCSK9 in the first place. The practical payoff is dosing: after two initial doses three months apart, you need only two injections per year.

In the ORION-1 trial, a single dose of inclisiran reduced apoB by about 23 percent, while a second dose brought the reduction to roughly 41 percent. The effect on apoB persisted for over 200 days after dosing.⁹ That durability is a significant advantage for people who struggle with adherence to daily pills or biweekly injections. The LDL-C lowering is broadly comparable to the monoclonal antibodies, though long-term cardiovascular outcomes data for inclisiran are still maturing.

Bempedoic Acid for Statin-Intolerant Patients

Roughly 5–10 percent of people prescribed a statin report muscle symptoms severe enough to stop taking it. Bempedoic acid was developed with that population in mind. It inhibits an enzyme called ATP-citrate lyase, which sits upstream of the enzyme that statins block. The key design feature is that bempedoic acid is a prodrug that only becomes active inside liver cells, sparing skeletal muscle entirely.¹⁰

On its own, bempedoic acid lowers LDL-C by roughly 18–21 percent, and when combined with ezetimibe in a fixed-dose pill, reductions climb to about 38 percent.¹¹ A meta-analysis confirmed that bempedoic acid also significantly reduced apoB levels compared with placebo.¹² The reductions are more modest than what you get from high-intensity statins or PCSK9 inhibitors, so bempedoic acid is best thought of as an oral option for people who genuinely cannot tolerate statins, rather than a replacement for them.

Therapies for Severe Genetic Conditions

Some people inherit mutations that cause extremely high LDL-C from birth. Homozygous familial hypercholesterolemia, the most severe form, can produce LDL-C levels above 500 mg/dL and coronary disease in childhood. Standard treatments often cannot bring levels down far enough, so several specialized therapies exist for this population.

Mipomersen

Mipomersen is an antisense oligonucleotide, a short strand of synthetic DNA that binds to the messenger RNA encoding apoB-100, preventing the liver from manufacturing the protein. By reducing apoB production directly, it lowers LDL-C by about 25–39 percent and Lp(a) by a similar range.¹³ Kinetic studies showed that mipomersen reduced apoB across the entire lipoprotein cascade, from VLDL through IDL to LDL.¹⁴ The trade-off is tolerability: injection-site reactions, flu-like symptoms, and fat accumulation in the liver are common enough that mipomersen is approved only for homozygous familial hypercholesterolemia in the United States and has seen limited uptake.⁸

Lomitapide

Lomitapide works at an even earlier step, blocking a protein called microsomal triglyceride transfer protein that the liver needs to assemble apoB-containing lipoproteins in the first place. Without this protein, the liver simply cannot package and secrete VLDL, so LDL production drops sharply.¹⁵ Like mipomersen, lomitapide carries a risk of liver fat accumulation and gastrointestinal side effects, and it is restricted to homozygous familial hypercholesterolemia patients under close monitoring.

Evinacumab

Evinacumab targets a completely different pathway. It is a monoclonal antibody against ANGPTL3, a protein that normally inhibits enzymes involved in breaking down triglyceride-rich lipoproteins. By blocking ANGPTL3, evinacumab reduces LDL-C through a mechanism that does not depend on LDL receptors, which is critical for people whose receptors are absent or barely functional. In a trial of homozygous familial hypercholesterolemia patients, evinacumab lowered LDL-C by about 47 percent compared with baseline, versus essentially no change with placebo.¹⁶ This receptor-independent action makes evinacumab a genuinely novel option for the hardest-to-treat patients.

Diet and Exercise

Lifestyle changes alone produce smaller apoB reductions than drugs, but they form the foundation on which everything else is built. The dietary effect is real and mechanistically interesting: reducing total fat intake appears to lower apoB primarily by slowing down production in the liver, while swapping saturated fat for polyunsaturated fat also cuts apoB synthesis.¹⁷ So the dietary advice you have heard for decades, eat less saturated fat and replace it with unsaturated fats, has a direct impact on the number of atherogenic particles your liver secretes.

Exercise adds something that diet alone does not always deliver. A year-long randomized trial in overweight men found that regular exercise significantly lowered apoB even though LDL-C itself barely budged.¹⁸ This is a perfect illustration of why apoB can tell a different story than LDL-C: the exercise shifted particle characteristics in a way that standard cholesterol tests missed. A separate study found that exercise-induced weight loss, rather than calorie restriction alone, was what drove reductions in apoB-containing lipoproteins.¹⁹ The takeaway is that being physically active matters for apoB independently of what the scale says, though losing weight through exercise amplifies the benefit.

Where ApoB Guidelines Stand

Despite strong evidence favoring apoB as a risk marker, guidelines have been slow to set consistent apoB targets. A 2024 review in Circulation noted that while clear LDL-C targets or treatment triggers exist, matching targets for apoB have lagged behind.²⁰ European guidelines have been more explicit, offering apoB thresholds of less than 65 mg/dL for very high-risk patients and less than 80 mg/dL for high-risk patients. More recent North American expert recommendations have proposed apoB goals that roughly mirror LDL-C targets: under 55, 70, or 90 mg/dL depending on cardiovascular risk category.

One practical reason apoB testing has not become universal is that most labs do not include it on a standard lipid panel. You typically have to request it specifically, and many clinicians are not yet in the habit of ordering it. The test itself is straightforward and inexpensive. A 2026 cost-effectiveness analysis found that the cost of apoB testing was marginal; most of the extra cost in apoB-guided strategies came from longer life expectancy and the prolonged preventive treatment that accompanies it, not from the blood test.²¹ That is a reassuring finding for anyone wondering whether asking for an apoB test is worth the bother.

When ApoB and LDL-C Disagree

The most clinically important scenario is when your LDL-C looks fine but your apoB is elevated. This discordance is especially common in people with metabolic syndrome, type 2 diabetes, or high triglycerides, conditions where the liver tends to produce lots of small, cholesterol-poor LDL particles. Each of those small particles still carries one apoB molecule, so the particle count can be high even though the total cholesterol cargo is not remarkable. In these situations, relying on LDL-C alone may underestimate risk, and the treatment response may look adequate on a standard lipid panel while apoB remains above goal.

If you fall into this discordant category, your clinician might consider adding a non-statin therapy even when your LDL-C looks acceptable. PCSK9 inhibitors, ezetimibe, and bempedoic acid all lower particle number alongside cholesterol content. Monitoring apoB during treatment ensures you are actually reducing the thing that predicts events, not just the thing that happens to be easiest to measure.

Gene Editing as a Future Possibility

The most futuristic approach to apoB-related treatment does not involve pills or injections at regular intervals at all. Researchers are exploring CRISPR-based gene editing as a potential one-time treatment. In animal studies, lipid nanoparticles carrying CRISPR machinery were delivered specifically to liver cells and knocked out the PCSK9 gene, producing a stable 60 percent drop in LDL-C with a single administration.²² The same technology has been extended in mice to target ANGPTL3 and various apolipoproteins. The appeal is obvious: instead of a lifetime of daily pills or periodic injections, a single treatment could permanently reprogram the liver’s cholesterol machinery.²³

Human trials of PCSK9 gene editing have begun, and early results in a handful of patients with heterozygous familial hypercholesterolemia have been encouraging. But “encouraging early results” is a long way from a proven, widely available therapy. The durability question, whether the edit truly lasts a lifetime, is unanswerable with only a few years of follow-up. And the irreversibility of gene editing raises a higher safety bar than a drug you can simply stop taking. Still, the concept of treating apoB at its genetic source rather than managing its downstream consequences represents a genuine paradigm shift. If the technology matures as hoped, the idea of taking a statin every day for decades may eventually seem as quaint as other medical practices we have outgrown.

Emerging Therapies Targeting Lp(a)

Lipoprotein(a) is an unusual member of the apoB family. It consists of an LDL-like particle with an extra protein, apolipoprotein(a), attached. Lp(a) levels are largely genetically determined and barely move with statins or lifestyle changes. That has made it a frustrating treatment target, but a new class of RNA-based therapies is changing the picture. Olpasiran and zerlasiran are antisense or siRNA drugs designed to slash Lp(a) production in the liver, and a recent network meta-analysis found that both were also associated with improvements in LDL-C and apoB concentrations.²⁴ Large cardiovascular outcomes trials for these agents are underway, and results over the next few years will determine whether lowering Lp(a), and the apoB it carries, translates into fewer heart attacks and strokes. For the roughly 20 percent of the population with elevated Lp(a), these drugs could fill a gap that no existing therapy addresses.